KEYNOTE-024: Extended Survival Outcomes With First-line Pembrolizumab in PD-L1+ NSCLC

Patients with high PD-L1 who started treatment with first-line pembrolizumab achieved better survival outcomes than those starting with first-line chemotherapy.